Oncology

This FAQ describes what oncology pharmacists should know ahead of Gynecologic Cancer Awareness Month in September.

August 2026 brought major oncology advances, including new FDA approvals and pivotal phase 3 data that expanded targeted, immune-based, and personalized treatment strategies.

August 2026 brought first-in-class approvals in multiple myeloma, warm autoimmune hemolytic anemia, and polycythemia vera alongside important findings involving bispecific antibodies, sickle cell pain, and infection risk.

Rusfertide gives adults with polycythemia vera a first-in-class option to cut phlebotomy dependence and control hematocrit.

Tarlatamab targets DLL3 in lung cancer; learn step-up dosing, CRS/ICANS monitoring, and pharmacy tips to keep patients safely on therapy.

Experts gather for a roundtable on the rare, delayed toxicities associated with ciltacabtagene autoleucel in relapsed/refractory multiple myeloma.

Early-phase trial data showed antitumor activity in heavily pretreated metastatic colorectal cancer.

If Heidi Overton is confirmed, the FDA nominee's views on abortion pills, vaccines, and drug review could reshape pharmacists' daily work.

Ivonescimab plus chemotherapy significantly improved overall survival compared with durvalumab plus chemotherapy in patients with previously untreated advanced biliary tract cancer.

Sunburn and tanning signal DNA damage—learn SPF 30+ sunscreen tips, reapplication, and medication photosensitivity for skin cancer prevention.

The FDA has approved 2 zanidatamab-hrii–based regimens following phase 3 results demonstrating significant improvements in progression-free survival.

The FDA has granted fast track designation to ERAS-0015, an investigational oral pan-RAS molecular glue that has shown early antitumor activity in previously treated KRAS G12X pancreatic ductal adenocarcinoma.

The FDA-granted priority review raises the possibility of an immunotherapy-first approach that could allow some patients to avoid chemotherapy, radiation, and surgery.

The FDA granted fast track designation to safusidenib, an investigational oral IDH1 inhibitor that produced durable responses in a phase 2 study of patients with treatment-naive grade 2 IDH1-mutant glioma.

Cardiomyopathy, hepatitis B, breast cancer, hypertension, and myeloma decisions land in the FDA's final-quarter queue.

Following community reports of more than 400 cancer cases in Keyport and Union Beach, New Jersey officials are expanding environmental sampling near a former landfill.

Decode carcinogens: IARC hazard vs risk, what "possibly" means, and how pharmacists ease aspartame, meat, and phone fears.

Mattew Lei, PharmD, BCOP,breaks down the FDA approval of subcutaneous isatuximab-irfc via the CirCLIQ on-body injector.

Intismeran autogene plus pembrolizumab significantly improved recurrence-free and distant metastasis-free survival over pembrolizumab alone.

In an interview with Pharmacy Times, Scott Soefje, PharmD, MBA, BCOP, FCCP, FHOPA, discussed how Inlexzo and increasingly complex urologic cancer therapies are driving closer coordination between urology and oncology pharmacy.

First-line trastuzumab deruxtecan significantly delayed disease progression in HER2-mutant advanced NSCLC.

The all-oral combination of osimertinib and savolitinib significantly improved progression-free and overall survival following osimertinib resistance.

The FDA's decision makes iberdomide the first approved CELMoD for patients with relapsed/refractory multiple myeloma.

Active surveillance increased from 27% in 2005 to 93% in 2024, reflecting a major shift away from immediate treatment for favorable-risk disease.

The warning has prompted new CDC recommendations for prevention and molecular diagnostic testing.

Inlexzo (gemcitabine intravesical system) reshapes NMIBC care: bladder‑dwelling therapy, J9183 billing, and coordinated pharmacy‑urology safety steps.

The combination also produced a 78.6% complete response rate in heavily pretreated patients with R/R mantle cell lymphoma following BTK inhibitor therapy.

Timed clinician prompts plus patient reminders boost annual LDCT follow-up to 75%, highlighting workflow fixes that close lung cancer screening gaps.